CN
UHPLC Analysis of Intact Infliximab on BIOshell IgG 1000 Å C4
Materials
analytical column
Product No.
Description
Pricing
mobile phase component
standard
Product No.
Description
Pricing
SILu™MAb Infliximab Stable-Isotope Labeled Monoclonal Antibody
recombinant, expressed in CHO cellsCONDITIONS
column
BIOshell IgG 1000 Å C4; 10 cm x 2.1 mm I.D., 2.7 μm particles (63288-U)
mobile phase
[A] 70:25:5, water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA); [B] 50:45:5, water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA)
gradient
0% B to 100% B in 15 min
flow rate
0.2 mL/min
pressure
1800 psi (122 bar)
column temp.
75 °C
detector
UV, 215 nm
injection
5 μL
sample
Infliximab, 100 μg/mL, water (0.05% TFA)
Description
Analysis Note
Infliximab (brand name Remicade) is an immunosuppressive biologic drug used to treat rheumatoid arthritis, psoriatic arthritis, Crohn′s disease, and many other diseases by blocking TNF alpha which prevents an autoimmune reaction. It has a molecular weight of ~150 kDa. The BIOshell IgG 1000 Å C4 UHPLC column yielded an efficient peak for this protein in less than five minutes.
Legal Information
null